Quality statements

Quality standard

Statement 1 People with cystic fibrosis have the results of all assessments they have had during the past year reviewed annually by a specialist multidisciplinary team.

Statement 2 People with cystic fibrosis have individual rooms with en-suite facilities when admitted to hospital as inpatients.

Statement 3 People with cystic fibrosis who have chronic Pseudomonas aeruginosa infection have sustained treatment with an inhaled antibiotic.

Statement 4 People with cystic fibrosis who have clinical evidence of lung disease are prescribed rhDNase^[1] as the first choice of mucoactive agent.

NICE has developed guidance and a quality standard on patient experience in adult NHS services (see the NICE Pathway on patient experience in adult NHS services), which should be considered alongside these quality statements.

Other quality standards that should be considered when commissioning or providing cystic fibrosis services include:

End of life care for infants, children and young people (2017) NICE quality standard 160
Transition from children's to adults' services (2016) NICE quality standard 140
Antimicrobial stewardship (2016) NICE quality standard 121
Medicines optimisation (2016) NICE quality standard 120
Healthcare-associated infections (2016) NICE quality standard 113
Infection prevention and control (2014) NICE quality standard 61
End of life care for adults (2011 updated 2017) NICE quality standard 13

A full list of NICE quality standards is available from the quality standards topic library.

^[1] At the time of publication (May 2018), rhDNase did not have a UK marketing authorisation for use in children under 5 years with cystic fibrosis for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.